Trials / Recruiting
RecruitingNCT07150975
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
A Multicenter, Randomized, Open-Label, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide(Wegovy®) in Adult Obese or Overweight Subjects
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- Sponsor
- Gan & Lee Pharmaceuticals. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR18 | Administered SC |
| DRUG | Semaglutide(Wegovy® ) | Administered SC |
Timeline
- Start date
- 2025-09-23
- Primary completion
- 2027-06-30
- Completion
- 2027-06-30
- First posted
- 2025-09-02
- Last updated
- 2025-11-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07150975. Inclusion in this directory is not an endorsement.